DAIC

FEBRUARY 27, 2024

Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort. Stroke is a major concern for millions of people living with atrial fibrillation, and as physicians, we strive to deliver better outcomes for these patients." The acquisition of Laminar, Inc.

Atrial Fibrillation 105

Atrial Fibrillation Innovation AFIB Pharmacology 105

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP339-AWP339, February 1, 2025. Background:Ischemic stroke triggers the metabolic reprogramming of cells in the infarct core and surrounding penumbra. Previous research in our lab supports a neuroprotective effect of PFKFB3 inhibition after stroke in young male mice.

Pharmacology 40

Pharmacology Stroke Strokes Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page AWP315-AWP315, February 1, 2024. Backgrounds:Our prior work demonstrated the potential of targeting miR-141-3p to mitigate ischemic stroke damage. Mice were sacrificed at 3 (acute) or 30 (chronic) days post-stroke.

Pharmacology 40

Pharmacology Stroke Strokes 40

The British Journal of Cardiology

NOVEMBER 29, 2023

Stroke is a major cause of mortality, morbidity and economic burden. Strokes can be thrombotic, embolic or haemorrhagic. The key risk factor for cardioembolic stroke is atrial fibrillation or flutter, and oral anticoagulation (OAC) is recommended in all but the lowest-risk patients with evidence of these arrhythmias.

Strokes 40

Strokes Stroke Risk Factors Blood Pressure 40

Journal of the American Heart Association

DECEMBER 1, 2023

BackgroundAn increased risk of recurrent stroke is noted in patients with atrial fibrillation despite direct oral anticoagulant (DOAC) use. A total of 84 patients experienced recurrent ischemic stroke after switching to different oral anticoagulants, with a total follow‐up time of 14 years. 0.39] for apixaban, 0.23 [95% CI, 0.14–0.37]

Atrial Fibrillation 75

Atrial Fibrillation Hemorrhage Pharmacology Strokes 75

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page A57-A57, February 1, 2025. Background:Acute ischemic stroke is a leading cause of death and disability in the U.S. Patients with an initial Alberta Stroke Program Early CT Score (ASPECTS)>6 were compared to those with ASPECTS < 6.

Stroke 40

Stroke Strokes Pharmacology Myocardial Infarction 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP380-ATP380, February 1, 2025. Although progress has been made, the role of lipid metabolism following stroke remains unclear. Recent research on neurodegenerative diseases has highlighted a pathophysiological cascade characterized by abnormal lipid accumulation within the brain.

Stroke 40

Stroke Strokes Pharmacology Cholesterol 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP344-ATP344, February 1, 2025. In a mouse model of ischemic stroke, we found that Chrdl1 is excessively upregulated in astrocytes in the peri-infarct area during the post-stroke plasticity window (230 days post-stroke in the mouse).

Stroke 40

Stroke Strokes Pharmacology 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP369-ATP369, February 1, 2025. In young mice, pharmacological activation or stimulation of the Vagus nerve has been shown to mitigate ischemic stroke injury by reducing brain and peripheral inflammation and oxidative stress.

Stroke 40

Stroke Strokes Pharmacology Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page ATP320-ATP320, February 1, 2024. Background:The complement C3a receptor (C3aR) plays a prominent role in deleterious post-stroke neuroinflammation. We and others have shown that either genetic deficiency of C3aR or its pharmacological inhibition in rodents protects against ischemic brain injury.

Stroke 40

Stroke Strokes Embolism Pharmacology 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP392-AWP392, February 1, 2025. In our lab, we have shown that Ripk2 contributes to secondary injury following ischemic stroke due to neuroinflammation. Additionally, pharmacologically inhibiting Ripk2 is neuroprotective and reduces infarction and deficits after stroke.

Stroke 40

Stroke Strokes Outcomes Pharmacology 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page AWP301-AWP301, February 1, 2024. We hypothesized that pharmacological inhibition of STAT3 activation in mice during the reperfusion phase after middle cerebral artery occlusion (MCAO) will lead to increased infarct size. Interestingly Stattic-treated mice had larger spleens (66.31 ± 5.40

Stroke 40

Stroke Strokes Pharmacology Ischemia 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page AWP317-AWP317, February 1, 2024. We also used flow sorted Ly6C hi and low monocytes for phagocytic uptake study obtained from perilesional ipsilateral mouse brain tissue of P2X4R KO and littermate WT mice after 3 or 7 days of stroke. and 2-fold P<0.05 and 2-fold P<0.05

Stroke 40

Stroke Strokes Pharmacology 40

Heart BMJ

JUNE 25, 2024

The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet.

Cardiovascular Disease 59

Cardiovascular Disease Myocardial Infarction Pharmacology Angina 59

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page ATP312-ATP312, February 1, 2024. Traumatic brain injury (TBI) afflicts 70 million people worldwide annually and is the 3rd overall risk factor for developing Alzheimer's disease (AD), behind genetics and aging.

Pharmacology 40

Pharmacology Risk Factors Stroke Strokes 40

Circulation

NOVEMBER 11, 2024

Despite comprehensive anticoagulation protocols, discrepancies in pharmacologic responses due to patient-specific factors such as adherence to anticoagulation, renal function, and genetics suggest that imaging studies may still be critical for patient safety. Mortality rates within a year did not differ significantly between the two groups.

Echocardiogram 40

Echocardiogram Atrial Fibrillation Stroke Strokes 40

Hypertension Journal

NOVEMBER 29, 2023

It is the main cause of lacunar stroke and a major source of vascular contributions to cognitive impairment and dementia. Knowledge gaps include initiating factors, molecular pathogenesis, relationships between arterial pathology and tissue damage, possible reversibility, pharmacological targets, and molecular biomarkers.

Dementia 64

Dementia Hypertension Pharmacology Biomarkers 64

Stroke Journal

MARCH 4, 2025

Stroke, Ahead of Print. Subarachnoid hemorrhage is a critical neurological condition accounting for about 5% of all strokes, and survivors experience long-term cognitive deterioration and increased risk of dementia. Management techniques reviewed include long-term cognitive health, such as endovascular coiling and surgical clipping.

Hemorrhage 40

Hemorrhage Genetic predisposition Genetic Markers Quality of Life 40

Journal of Clinical Investigation - Cardiology

AUGUST 1, 2024

Cerebral arteriovenous malformations represent the most common form of vascular malformations and can cause recurrent bleeding and hemorrhagic stroke. This discovery provides a promising entry point for preventive pharmacological interventions. The current issue of the JCI features an article by Zhao et al.

Pharmacology 40

Pharmacology Article Hemorrhage Stroke 40

Circulation

DECEMBER 28, 2023

Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease.

Atherosclerosis 49

Atherosclerosis Peripheral Arterial Disease Coronary Artery Disease Pharmacology 49

ADN Center of Excellence

SEPTEMBER 2, 2024

This miscommunication can cause blood to pool in the atria, increasing the risk of clot formation, which can then lead to strokes. AFib is associated with a fivefold increased risk of stroke, and it is also linked to heart failure, chronic fatigue, and other serious health issues.

AFIB 59

AFIB Atrial Fibrillation Innovation Heart Rhythm 59

Journal of the American Heart Association

DECEMBER 29, 2023

AF increases the risk of stroke, heart failure, dementia, and hospitalization. However, studies on how obesity affects pharmacologic or interventional AF treatments are limited. Journal of the American Heart Association, Ahead of Print. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Pharmacology 45

DAIC

APRIL 7, 2024

High blood pressure, or hypertension , is a leading cause of heart attacks, strokes and death. “In most cases, these differences persisted at six-month follow up despite the addition of other antihypertensive treatments. No new serious safety concerns were observed.”

Blood Pressure 111

Blood Pressure Heart attacks Heart Attack Hypertension 111

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP189-ATP189, February 1, 2025. Contributing factors such as hypocholesterolemia and hypertension amplify the risk of ICH and subsequent hematoma expansion, underscoring the urgent need for effective interventions.

Hemorrhage 40

Hemorrhage Pharmacology Hypertension Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page AWP51-AWP51, February 1, 2024. Background:Stroke is a debilitating condition and patients with acute stroke usually stays about a week in the acute hospital. The APN would identify stroke patients admitting to CH for further rehabilitation.

Nursing 40

Nursing Hospital Outpatient Strokes 40

Journal of the American Heart Association

APRIL 10, 2025

BackgroundPoststroke depression (PSD) is a prevalent neuropsychiatric complication of stroke. HCN channels were downregulated by pharmacological inhibitor or neuronspecific adenoassociated virus. Journal of the American Heart Association, Ahead of Print. However, the mechanisms underlying PSD are still unclear.

Ischemia 40

Ischemia Pharmacology Stroke Strokes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page A103-A103, February 1, 2024. Introduction:Damage in the ischemic core and penumbra after stroke affects patient prognosis. Microglia immediately respond to ischemic insult after stroke. However, the microglial heterogeneity and the underlying mechanisms remain unclear.

Ischemia 40

Ischemia Pharmacology Strokes Stroke 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP364-ATP364, February 1, 2025. This suggests that intranasally targeting the NgR1 pathway may be a viable pharmacologic mechanism of facilitating neuronal recovery in patients exposed to air pollution.

Pharmacology 40

Pharmacology Stroke Strokes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page AWP322-AWP322, February 1, 2024. Hyperhomocysteinemia (Hhcy), a metabolic disorder is recognized as a risk factor for ischemic stroke. However, the impact of Hhcy on stroke outcome is not known.

Ischemia 40

Ischemia Pharmacology Strokes Stroke 40

ADN Center of Excellence

SEPTEMBER 2, 2024

This miscommunication can cause blood to pool in the atria, increasing the risk of clot formation, which can then lead to strokes. AFib is associated with a fivefold increased risk of stroke, and it is also linked to heart failure, chronic fatigue, and other serious health issues.

AFIB 52

AFIB Atrial Fibrillation Innovation Heart Rhythm 52

DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Stroke Journal

DECEMBER 21, 2023

Stroke, Ahead of Print. The motivation for developing a suitable PRES model is 2-fold: to fill in knowledge gaps of the pathophysiological mechanisms involved, and to open new perspectives for clinical assessment of pharmacological targets to improve therapeutic management of PRES.

Hypertension 40

Hypertension Pharmacology Diet Research 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP31-AWP31, February 1, 2025. Neurovascular disorders- including stroke, brain aneurysm, and vascular malformations- strike an estimated seven million Americans annually and can lead to vascular pathologies, neurological disability, and death.

Pharmacology 40

Pharmacology Aneurysm Stroke Strokes 40

DAIC

JANUARY 23, 2024

3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 mg) to reduce the risks of heart attack, stroke, coronary revascularization, and CV death.29 4 In the U.S. 22 In general, hsCRP values above 2.0

Cardiovascular Disease 111

Cardiovascular Disease Heart attacks Heart Attack Coronary Artery Disease 111

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP400-AWP400, February 1, 2025. SARS-COV-2 causes neurological and cognitive impairments and aggravates Alzheimers Disease-Related Dementia (ADRD). Yet, the molecular mechanism is not fully understood.

Dementia 40

Dementia COVID-19 Pharmacology Stroke 40

Stroke: Vascular and Interventional Neurology

DECEMBER 8, 2024

Stroke: Vascular and Interventional Neurology, Ahead of Print. BACKGROUNDLocal angiotensin activity is thought to play a critical role in arterial wall homeostasis and remodeling, and impaired arterial wall integrity contributes to the pathogenesis of subarachnoid hemorrhage (SAH).

Hypertension 40

Hypertension Hemorrhage Pharmacology Aneurysm 40

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database ( [link] ).

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Drug Costs Myocardial Infarction 45